We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI icon
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$812B
$175M 12.47%
+465,000
New +$190M
2022 Q2
0 quarters
BHVN icon
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$92.2M 6.56%
632,794
-11,872
-2% -$1.52M
2021 Q4
2 quarters
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$480B
$75.7M 5.38%
270,000
+90,000
+50% +$27.9M
2021 Q4
2 quarters
UTHR icon
4
United Therapeutics
UTHR
$22.9B
$73.2M 5.21%
310,834
+18,600
+6% +$3.78M
2020 Q2
8 quarters
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$71M 5.04%
889,583
+279,644
+46% +$26.5M
2020 Q2
8 quarters
GSK icon
6
GSK
GSK
$99.5B
$69.9M 4.97%
1,275,297
+267,967
+27% +$14.8M
2018 Q1
17 quarters
GSK icon
7
CALL
GSK
GSK
$99.5B
$67.6M 4.81%
1,242,960
– –
2020 Q4
6 quarters
AZN icon
8
AstraZeneca
AZN
$258B
$67.4M 4.79%
510,165
+137,533
+37% +$18M
2019 Q4
10 quarters
DHR icon
9
Danaher
DHR
$162B
$45.6M 3.24%
202,655
+22,437
+12% +$5.17M
2018 Q3
15 quarters
SNY icon
10
Sanofi
SNY
$96.8B
$44M 3.13%
+879,460
New +$46.7M
2022 Q2
0 quarters
AVTR icon
11
Avantor
AVTR
$11B
$34.8M 2.48%
1,120,175
+124,943
+13% +$3.9M
2020 Q4
6 quarters
TEVA icon
12
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
$33.9M 2.41%
4,510,702
+367,100
+9% +$3.2M
2020 Q3
7 quarters
CYH icon
13
Community Health Systems
CYH
$426M
$30.2M 2.15%
8,060,859
+934,148
+13% +$6.58M
2020 Q4
6 quarters
XBI icon
14
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$26.4M 1.88%
+356,067
New +$26.7M
2022 Q2
0 quarters
NVST icon
15
Envista
NVST
$3.72B
$25.4M 1.81%
659,094
+89,743
+16% +$3.77M
2020 Q4
6 quarters
BIIB icon
16
Biogen
BIIB
$34.8B
$20.7M 1.47%
101,414
+23,411
+30% +$4.79M
2021 Q4
2 quarters
ELV icon
17
Elevance Health
ELV
$93.3B
$20.6M 1.47%
42,785
+10,334
+32% +$5.11M
2020 Q4
6 quarters
AZN icon
18
CALL
AstraZeneca
AZN
$258B
$19.8M 1.41%
150,150
-136,000
-48% -$17.8M
2021 Q3
3 quarters
AMRN icon
19
Amarin Corp
AMRN
$244M
$19.8M 1.41%
664,245
+215,238
+48% +$9.29M
2018 Q1
17 quarters
CNC icon
20
Centene
CNC
$34.5B
$19.8M 1.41%
233,647
+114,477
+96% +$9.51M
2021 Q1
5 quarters
XBI icon
21
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$19.3M 1.37%
+259,800
New +$19.5M
2022 Q2
0 quarters
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.17B
$19.1M 1.36%
+994,362
New +$16.6M
2022 Q2
0 quarters
ARGX icon
23
argenx
ARGX
$51.5B
$18.6M 1.32%
49,136
+25,994
+112% +$8.37M
2021 Q3
3 quarters
FATE icon
24
Fate Therapeutics
FATE
$226M
$18M 1.28%
726,586
+270,527
+59% +$7.46M
2018 Q4
14 quarters
AMRX icon
25
Amneal Pharmaceuticals
AMRX
$6.65B
$17.5M 1.24%
5,494,280
+2,783
+0.1% +$10.1K
2020 Q2
8 quarters
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.